Prescription Drug Actos
Actos is a prescription drug approved by the FDA to treat type 2 diabetes. Plaintiffs in the consolidated litigations in Illinois, California and the U.S. District Court, Western District of Louisiana, allege that as a result of using Actos, they had an increased risk of developing bladder cancer and that manufacturers Eli Lilly Co. and Takeda Pharmaceutical concealed the risk, as well as failed to provide adequate warnings to the public.
In April 2015, Takeda agreed to settle thousands of pending Actos lawsuits for $2.37 billion contingent upon participation by 95% of the eligible plaintiffs. On September 12, 2015, the participation threshold was met. The total fund could rise to $2.4 billion if the participation rate increases to 97%. To be eligible for payment from the fund, a claimant must have used Actos on or before December 11, 2011 and been diagnosed with cancer of the bladder, renal pelvis or ureter.